As of November 6, 2026, Matinas BioPharma Holdings, Inc. is a publicly traded company (NYSE: MTNB). The largest holder reporting an active stake on Schedule 13D is Sanitam Partners LLC, at 9.99%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Lazar David E. (9.81%), Hezbay Holdings LLC (9.54%) (Schedule 13D/A, August 13, 2026).
Is this your company?
About to sign with, pay or invest in Matinas BioPharma Holdings, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Matinas BioPharma Holdings, Inc. a real, registered company?
- Matinas BioPharma Holdings, Inc. files with the SEC under CIK 1582554 (its SEC filings).
- Its shares are listed under the ticker MTNB on NYSE (SEC company record).
- Incorporated in Delaware; business address in Bedminster, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Matinas BioPharma Holdings, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Robin L. Smith (Form 8-K filed 2026-07-13). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Sanitam Partners LLC (filed 2026-08-13).
Who are Matinas BioPharma Holdings, Inc.'s owners and officers?
Matinas BioPharma Holdings, Inc.: incorporated in Delaware; business address in Bedminster, New Jersey; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-08-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-02-19)
- : Executive Officer (Form D, 2025-02-19)
- : Director (Form D, 2025-02-19)
- : Director (Form D, 2025-02-19)
- : Director (Form D, 2025-02-19)
- : Director (Form D, 2025-02-19)
- : Director (Form D, 2025-02-19)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-08-13 | Sanitam Partners LLC | 9.99% |
| Schedule 13G, 2026-07-14 | Hezbay Holdings LLC | 9.54% |
| Schedule 13G/A, 2025-11-14 | Highbridge Capital Management, LLC | 0% |
| Schedule 13D/A, 2025-09-25 | Hezbay Holdings LLC | 4.99% |
| Schedule 13G, 2025-08-19 | Lazar David E. | 9.81% |
| Schedule 13G/A, 2025-08-14 | Highbridge Capital Management, LLC | 8.4% |
Questions about who owns Matinas BioPharma Holdings, Inc.
Who owns Matinas BioPharma Holdings, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Matinas BioPharma Holdings, Inc.: Sanitam Partners LLC (9.99%, Schedule 13D/A, filed 2026-08-13), Lazar David E. (9.81%, Schedule 13G, filed 2025-08-19) and Hezbay Holdings LLC (9.54%, Schedule 13G, filed 2026-07-14).
Who are the largest shareholders of Matinas BioPharma Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Matinas BioPharma Holdings, Inc. on this page are Sanitam Partners LLC (9.99%), Lazar David E. (9.81%) and Hezbay Holdings LLC (9.54%).
When did Sanitam Partners LLC buy into Matinas BioPharma Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sanitam Partners LLC on this page is the Schedule 13D/A, filed 2026-08-13, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Matinas BioPharma Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Matinas BioPharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Matinas BioPharma Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-13 | Robin L. Smith | departed | 2026-07-12 |
Which insiders own Matinas BioPharma Holdings, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 1,231,445 shares (8.4% of shares outstanding), 28,260 held directly and 1,203,185 indirectly (Form 4, 2026-08-13).
- , a 10% owner: 1,500 shares (0.01% of shares outstanding) (Form 4/A, 2025-04-10).
Shares outstanding: 14,692,796 as of 2026-08-10, from the company's latest SEC cover page.
How much has Matinas BioPharma Holdings, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-02-19 | $1.65M | $3.30M |
Keep reading
More on Matinas BioPharma Holdings, Inc. and the records around it.
Matinas BioPharma Holdings, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jul 2026
Companies that share a holder
- Lazar David E. also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), MAINZ BIOMED N.V. (Aug 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/matinas-biopharma